Document Detail

Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT).
MedLine Citation:
PMID:  15302679     Owner:  NLM     Status:  MEDLINE    
1. The aim was to test the hypothesis that nitric oxide (NO) donor drugs can inhibit the 5-hydroxytryptamine (5-HT) transporter, SERT. 2. The NO donors, MAHMA/NO (a NONOate; (Z)-1-[N-methyl-N-[6-(N-methylammoniohexyl)-amino]]diazen-1-ium-1,2-diolate), SIN-1 (a sydnonimine; 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium chloride), FK409 (an oxime; (+/-)-(4-ethyl-2E-(hydroxyimino)-5-nitro-3E-hexenamide)) and peroxynitrite, but not Angeli's salt (source of nitroxyl anion) or sodium nitrite, caused concentration-dependent inhibition of the specific uptake of [3H]-5-HT in COS-7 cells expressing human SERT. 3. Superoxide dismutase (150 U ml(-1)) plus catalase (1200 U ml(-1)), used to remove superoxide and hence prevent peroxynitrite formation, prevented the inhibitory effect of SIN-1 (which generates superoxide) but not of MAHMA/NO or FK409. 4 The inhibitory effects of the NO donors were not affected by the free radical scavenger, hydroxocobalamin (1 mM) or the guanylate cyclase inhibitor, ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one; 3 microM). 5. L-Cysteine (1 mM; source of excess thiol residues) abolished or markedly reduced the inhibitory effects of MAHMA/NO, SIN-1, FK409 and peroxynitrite. 6. It is concluded that inhibition of SERT by the NO donors cannot be attributed exclusively to NO free radical nor to nitroxyl anion. It does not involve guanosine-3',5'-cyclic monophosphate, but may involve nitrosation of cysteine residues on the SERT protein. Peroxynitrite mediates the effect of SIN-1, but not the other drugs. 7. Data in mice with hypoxic pulmonary hypertension suggest that SERT inhibitors may attenuate pulmonary vascular remodelling. Thus, NO donors may be useful in pulmonary hypertension, not only as vasodilators, but also because they inhibit SERT, provided they display this effect in vivo at appropriate doses.
Lesley J Bryan-Lluka; Marisa H Papacostas; Filip A Paczkowski; Janet C Wanstall
Related Documents :
2169299 - Measurement of reactive oxygen metabolites produced by human monocyte-derived macrophag...
12833209 - Growth inhibition of the filamentous fungus aspergillus nidulans by cadmium: an antioxi...
19518649 - Atomic scale structure of (001) hydrogen-induced platelets in germanium.
23659589 - Munc13-4 mediated secretion is essential for infarct progression but not intracranial h...
12009849 - Nitric oxide-mediated depletion of langerhans cells from the epidermis may be involved ...
2189749 - Effects of isoxazolyl-naphthoquinoneimines on growth and oxygen radical production in t...
7925979 - Interleukin-8 processing by neutrophil elastase, cathepsin g and proteinase-3.
8910939 - Effects of native and oxidation-resistant secretory leukoprotease inhibitor on cystic f...
381069 - Particular rna fragments as promoters of leukocyte and platelet formation in rabbits.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2004-08-09
Journal Detail:
Title:  British journal of pharmacology     Volume:  143     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-03     Completed Date:  2005-02-09     Revised Date:  2013-06-09    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  63-70     Citation Subset:  IM    
Department of Physiology & Pharmacology, School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Transport / drug effects
COS Cells
Catalase / pharmacology
Cercopithecus aethiops
Culture Media
Cysteine / pharmacology
DNA, Complementary / genetics,  metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors / pharmacology
Free Radical Scavengers / pharmacology
Guanylate Cyclase / antagonists & inhibitors
Hydroxocobalamin / pharmacology
Membrane Glycoproteins / antagonists & inhibitors*,  metabolism*
Membrane Transport Modulators*
Membrane Transport Proteins / antagonists & inhibitors*,  metabolism*
Nerve Tissue Proteins / antagonists & inhibitors*,  metabolism*
Nitric Oxide Donors / pharmacology*
Nitro Compounds / pharmacology
Oxadiazoles / pharmacology
Peroxynitrous Acid / pharmacology
Piperazines / pharmacology
Quinoxalines / pharmacology
Serotonin / metabolism*
Serotonin Plasma Membrane Transport Proteins
Superoxide Dismutase / pharmacology
Reg. No./Substance:
0/1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; 0/Culture Media; 0/DNA, Complementary; 0/Enzyme Inhibitors; 0/Free Radical Scavengers; 0/Membrane Glycoproteins; 0/Membrane Transport Modulators; 0/Membrane Transport Proteins; 0/Nerve Tissue Proteins; 0/Nitric Oxide Donors; 0/Nitro Compounds; 0/Oxadiazoles; 0/Piperazines; 0/Quinoxalines; 0/SLC6A4 protein, human; 0/Serotonin Plasma Membrane Transport Proteins; 13422-51-0/Hydroxocobalamin; 14691-52-2/Peroxynitrous Acid; 50-67-9/Serotonin; 52-90-4/Cysteine; 67469-78-7/vanoxerine; 92454-60-9/FK 409; EC; EC Dismutase; EC Cyclase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased r...
Next Document:  In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-15...